~~<i id='04AB6D587B'><strike id='04AB6D587B'><tt id='04AB6D587B'><pre id='04AB6D587B'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：Wikipedia 2025-10-02 19:25:31 Page View：74868

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Harvard's Jason Buenrostro wins MacArthur grant for genetics work
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

explore

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Whyarerichbiotechscuttingcosts?HasJPMWeekalreadywornoff?Andwhat’sgoingtomovemarketsin2024?Wecoverall

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

New brain studies show LSD's effects on the brain in full color

AlexHogan/STATWhenLSDwasmadeillegalinthelate1960s,mostlaboratoryresearchonthedrugwaslikewise suspend